ripekg:evaluation/RIPEA237F9DCBC31EFBBD |
prov:used |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
rdfs:Resource |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
owl:Thing |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
ripe:RegistryEvidenceRegistry evidence |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
tido:Evidence |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
prov:wasAttributedTo |
ripekg:source/clinicaltrials-govClinicalTrials.gov |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA237F9DCBC31EFBBD |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA237F9DCBC31EFBBD |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
ripe:concerns |
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
ripe:isProspective |
true |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
ripe:registrationAssessmentRationale |
Registration date is on or before LLM recruitment start date. |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
ripe:registrationDate |
27-07-2015 |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
ripe:registrationId |
NCT02512315 |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
ripe:registrationLink |
https://clinicaltrials.gov/study/NCT02512315 |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
ripe:registryName |
ClinicalTrials.gov |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA237F9DCBC31EFBBD-human-2-2 |
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA237F9DCBC31EFBBD-inspectai-2-2 |